- Published at
- by en.globes.co.il
mixed
mixed
Mon: Tower leads TASE lower
Chip companies Tower, Camtek and Nova led the declines today as Ormat bucked the market.
News for Teva Pharmaceutical Industries Limited (TEVA)
- Published at
- by en.globes.co.il
neutralneutral- Published at
- by benzinga.com
neutralneutralThis Is What Whales Are Betting On Teva Pharmaceutical Indus - Teva Pharmaceutical Indus (NYSE:TEVA)
Financial giants have made a conspicuous bullish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus TEVA revealed ...- Published at
- by en.globes.co.il
mixedmixedWed: TASE sharply higher amid continued volatility
Elbit Systems continued its strong gains as Delek and NewMed Energy led the declines.- Published at
- by en.globes.co.il
mixedmixedTue: TASE tumbles on Trump tariff fears
Teva and the banks felt sharply today as Elbit Systems kept climbing.- Published at
- by financialpost.com
mixedmixedTeva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s Preside…- Published at
- by gurufocus.com
positivepositiveINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeu- Published at
- by en.globes.co.il
mixedmixedMon: Elbit Systems fuels strong TASE gains
Elbit Systems and the banks rose strongly today as Energix led the declines.- Published at
- by en.globes.co.il
mixedmixed- Published at
- by insidermonkey.com
mixedmixedIs Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts?
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts.- Published at
- by en.globes.co.il
mixedmixedWed: TASE back on the rise
Camtek led the gains today as NICE Systems and ICL fell back.- Published at
- by insidermonkey.com
positivepositive12 Best Low Price Pharma Stocks To Invest In Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...- Published at
- by financialpost.com
positivepositiveTeva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults1 L…- Published at
- by en.globes.co.il
mixedmixed- Published at
- by insidermonkey.com
positivepositiveTeva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks
We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands ...- Published at
- by en.globes.co.il
mixedmixedMon: TASE continues to lose ground
ICL and Teva fell today as Shufersal bucked the market.- Published at
- by seekingalpha.com
neutralneutralTeva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference February...- Published at
- by en.globes.co.il
mixedmixed- Published at
- by gurufocus.com
mixedmixedTeva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitu- Published at
- by manilatimes.net
mixedmixed